Trials / Completed
CompletedNCT04369950
Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- The University of Texas Health Science Center, Houston · Academic / Other
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to show that the effect of 3% 2-chloroprocaine prior to epidural morphine administration will be not inferior to the effect of epidural 2% lidocaine with 1:200,000 epinephrine on total opioid use for 24h
Conditions
- Physiological Effect of Drugs
- Morphine
- Analgesics
- Analgesics, Opioid
- Central Nervous System Depressants
- Narcotics
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 2% lidocaine with 1:200,000 epinephrine and epidural morphine | Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written. |
| DRUG | 3% 2-chloroprocaine and epidural morphine | Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written. |
Timeline
- Start date
- 2020-05-11
- Primary completion
- 2021-05-11
- Completion
- 2021-07-11
- First posted
- 2020-04-30
- Last updated
- 2022-05-26
- Results posted
- 2022-05-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04369950. Inclusion in this directory is not an endorsement.